Alnylam Pharmaceuticals | ALNY - Interest Expense On Debt


Alnylam Pharmaceuticals reported $82.05M in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Alnylam Pharmaceuticals USD 82.05M 12.76M Jun/2026
Amgen USD 95.64B 94.98B Jun/2026
Arrowhead Research USD 24.56M 716K Jun/2026
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
BioMarin Pharmaceutical USD 63.29M 48.34M Jun/2026
Incyte USD 582K 13K Jun/2026
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
Moderna USD 10.96B 527M Jun/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 281M 8M Sep/2025
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sanofi EUR -25M 99.78M Dec/2025
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Takeda JPY 63.85B 20.2B Jun/2026
Tectonic Therapeutic USD 246.58M 246.56M Mar/2026
Ultragenyx Pharmaceutical USD 22M 1000K Jun/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Xencor USD 7.35M 2.65M Jun/2026